ライフサイエンスコーパス: transplant donor

1 epidermal allografting from the bone marrow transplant donor.

2 ater overall HLA match between the blood and transplant donor.

3 d donor lymphocyte infusions (DLIs) from the transplant donor.

4 patients lacking a suitable bone marrow (BM) transplant donor.

5 tes, higher body mass index, and a cadaveric transplant donor.

6 om 11 coronary artery disease patients and 1 transplant donor.

7 in VSMCs isolated from 151 multiethnic heart transplant donors.

8 of renal disease, including potential kidney transplant donors.

9 for determining their eligibility as kidney transplant donors.

10 nce of oncogenic HPV and no convergence with transplant donors.

11 of hyperfiltration-associated CKD as seen in transplant donors.

12 old ischemic time for adult, deceased kidney transplant donors.

13 able with prior data for normal human kidney transplant donors.

14 atients and their HLA-C-mismatched unrelated transplant donors.

15 of sepsis patients vs cancer patients and vs transplant donors.

16 uring the risk evaluation of potential renal transplant donors.

17 e general safety of this approach for normal transplant donors.

18 osis, and evaluation of living-related liver transplant donors.

19 HGF) mobilize potential tolerogenic cells in transplant donors.

20 tured aortic ECs derived from multiple heart transplant donors.

21 cines could be used either in patients or in transplant donors.

22 promoter (Flk-1/LZ or Tie-2/LZ) were used as transplant donors.

23 and 520 HLA-DQ-mismatched patients and their transplant donors according to well-established crystall

24 ick figure field counseling for living renal transplant donors accurately provides information to bot

25 s deceased), recipient age, diagnosis, prior transplant, donor age, and donor cause of death.

26 sely affecting survival included the year of transplant, donor age, and donor-recipient gender mismat

27 on land mass, population, livers discarded, transplanted, donor age, or recipient MELD scores.

28 r 2002, 2,597 primary cadaveric kidney-alone transplants (donor age 5-45 years, recipient age 2-20 ye

29 MHC class I mismatch between transplant donor and recipient can create a situation of

30 lished that a mismatch for MICA A5.1 between transplant donor and recipient is critical for BKPyV rea

31 Among the 72 980 transplant donor and recipients included in the study (m

32 ially involved in overlapping care of the HC transplant donor and the recipient.

33 We genotyped 435 pancreas transplant donors and 431 recipients who had undergone p

34 equencing on lung tissue obtained from eight transplant donors and eight recipients with pulmonary fi

35 positivity in the absence of HBsAg in organ transplant donors and in candidate patients for chemothe

36 othelial glycocalyx breakdown occurs in lung transplant donors and recipients and predicts organ acce

37 te antigen (HLA) proteins mismatched between transplant donors and recipients cause allograft loss, y

38 was sought in an independent group of kidney transplant donors and recipients from Dublin, Ireland us

39 In our cohort, hematopoietic stem cell transplant donors and recipients were CMV seronegative a

40 quences of tobacco smoke exposure in cardiac transplant donors and recipients with an emphasis on all

41 ARTICIPANTS: This cohort study included lung transplant donors and recipients with race and ethnicity

42 In this cohort study of lung transplant donors and recipients, socioeconomic position

43 psychosocial issues among transgender kidney transplant donors and recipients.

44 pulations of racially and ethnically diverse transplant donors and recipients.

45 Participants included adult deceased liver transplant donors and waitlist candidates in the Organ P

46 aluated among 4 groups: 7/8 bidirectional MM transplants (donor and recipient heterozygous MM, n = 13

47 ne system was tolerant to host, mESC, and BM transplant donor antigens.

48 EC cultures prospectively isolated from the transplant donor at the time of transplantation.

49 ategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.

50 h persistent chimerism preferentially in the transplanted donor bone.

51 One hundred eight healthy liver transplant donor candidates were examined with two MR ch

52 eath (AICD) of anti-recipient T cells within transplant donor cell populations, with the goal of redu

53 d knowledge of the phenotype and function of transplanted donor cells facilitate strategies to optimi

54 zed that the increased replicative stress on transplanted donor cells in the recipient could lead to

55 m could be overcome by selectively expanding transplanted donor cells until they replace enough of th

56 ngraftment by promoting the proliferation of transplanted donor cells.

57 CAR-T products were derived from previous transplant donors (Cohort A) or newly matched donors (Co

58 gy, and the potential benefit of routine pre-transplant donor CrAg screening using lateral flow assay

59 To address this, transplant donor criteria have been expanded and, for ex

60 le cells isolated from 151 multiethnic heart transplant donors cultured under quiescent or proliferat

61 most common bacterial causes of solid-organ transplant donor-derived infection reported in transplan

62 t COVID-19 infection of deceased solid organ transplant donors does not affect recipient survival.

63 Bleeding of the transplanted donor duodenum can present as a late compli

64 hibit little or no antibody specific for the transplant donor during the early weeks and months after

65 Living kidney transplant donors generally have a favorable renal funct

66 y identified a potential biomarker for liver transplant donor graft quality.

67 biomarker pertaining to the quality of liver transplant donor grafts.

68 A severe shortage of human transplant donors has sparked interest in the use of ani

69 he preoperative screening of potential renal transplant donors has undergone a major evolution with t

70 ns of leukocytes collected from the original transplant donor have been used to induce a direct graft

71 entration, and compared with myocardium from transplant donor hearts.

72 ed tumors are de novo tumors that develop in transplanted donor hematogenous or lymphoid cells after

73 Early after transplant, donor HIV was transiently detected in five o

74 a direct relationship between the number of transplanted donor HLA-A2-expressing cells and the perce

75 suggested that host HSCs can be replaced by transplanted donor HSCs, even in the absence of cytoredu

76 ndogenous HSCs and facilitate engraftment of transplanted donor HSCs.

77 l and thus prevent productive engraftment of transplanted donor HSCs.

78 Recognition that transplanted donor immune cells can cure patients with l

79 l population, since long-bone removal or pre-transplant donor irradiation prevented long-term engraft

80 LAM cells arise from the patient or the lung transplant donor is an area of controversy.

81 Enhanced HLA matching between the blood and transplant donor is more likely to result in a DSA and T

82 (steroid, i.e., the "T4 Protocol") in organ transplant donors, is becoming increasingly used.

83 , when lower doses (50 or 25) of islets were transplanted, donor islets in the pancreas were much mor

84 Here, we validated the use of deceased transplant donor kidneys as a good model to study acute

85 For example, transplanting donor kidneys > or =55 yr old into recipie

86 Fifteen transplant donor livers served as controls.

87 The percentage of transplanted donor livers meeting marginal quality crite

88 seen (3.2%) in sections from a truly normal transplant donor lung.

89 Transplanted donor lymphocytes infused during hematopoie

90 tokines can stimulate the differentiation of transplanted donor marrow cells into the osteopoietic li

91 e MC would promote tolerance of subsequently transplanted donor-matched intestinal allografts without

92 Overall, 19 504 lung transplant donors (median [IQR] age, 33 [23-46] years; 3

93 tes that B cells respond specifically to the transplant donor more often than previously thought.

94 Transplanting donor MyD88(-/-) conventional T cells (Tco

95 e genotyped donors managed by the California Transplant Donor Network from 2001 to 2008 for the 4G/5G

96 ntial organ donors managed by the California Transplant Donor Network from 2001 to 2008.

97 ntial organ donors managed by the California Transplant Donor Network from 2002 to 2007.

98 lated from the ascending aortas of 151 heart transplant donors of various genetic ancestries in quies

99 Patients received DLI from their original transplant donors on a bulk-dose (n = 34) or on an escal

100 obotic assistance with other gynecologic and transplant donor operations, we adopted a robot-assisted

101 hs after transplant, irrespective of the pre-transplant donor or recipient vaccinations.

102 a; control lungs (n = 20) were obtained from transplant donors or from lung cancer resections.

103 This would establish the theoretical risk of transplanting donor organs from a patient with a known r

104 id recipients with no germ cells of its own, transplanted donor PGCs may exclusively form gametes.

105 4 beta 1 in vivo interaction to increase the transplant donor pool through modulation of marginal ste

106 Transplanted donor pre-pDCs expanded in vivo for 2 weeks

107 Augmented endothelial HIF-2alpha in transplant donors promoted airway microvascular integrit

108 me-dependent covariate, adjusted for year of transplant, donor quality, ischemic time, and candidate

109 Solid organ transplant donor-recipient eplet mismatch has been corre

110 CA) in BKPyV reactivation in a cohort of 144 transplant donor/recipient pairs, including recipients w

111 -mismatched healthy volunteers and prekidney transplant donor/recipient pairs.

112 ared trends in the utilization rates (hearts transplanted/donors recovered) of HCV-uninfected (HCV-)

113 ion in GVHD was associated with expansion of transplanted donor regulatory T cells and with tissue-sp

114 The pre-transplant donor's and recipient's serological status is

115 ailed imatinib but has a possible allogeneic transplant donor, should one offer dasatinib or nilotini

116 Postkidney transplant donor-specific antibodies (DSA) have been ide

117 ant sera, and they were associated with post-transplant donor-specific HLA antibodies, antibody-media

118 was to assess the impact of "preformed" (at transplant) donor-specific anti-HLA antibody (DSA) and f

119 e of ST2), Ifng, Csf2, Stat5, Batf, and Jak2 Transplanting donor ST2(-/-) Tcons with WT or ST2(-/-) T

120 atherosclerosis is supported by necropsy and transplant donor studies.

121 Analysis of circulating post-transplant donor T cells suggests that they undergo sele

122 sease (GVHD) is a T-cell-mediated disease of transplanted donor T cells recognizing host alloantigens

123 plays a role in the homeostatic survival of transplanted donor T cells.

124 to induce tolerance to kidney allografts by transplanting donor thymic grafts simultaneously with th

125 in 6 cases, suggesting transmission from the transplant donor to the recipient, despite recipient ser

126 d frequent transmission of JCPyV from kidney transplant donors to recipients.

127 nalytical model was generated to match liver transplant donors to waitlist candidates based on predef

128 idney samples from patients and seven living transplant donors (to serve as controls).

129 In rodent models, investigators have transplanted donor tracheas into a recipient rat's abdom

130 Kidney transplant donor type (deceased vs living).

131 Sex, ischemia time, race, previous transplant, donor type, nephrectomy technique, and stent

132 Mixed chimeras accepted subsequently transplanted donor-type rat hearts (>100 days) without i

133 fic CD8+ T cells from the blood of stem cell transplant donors using staining with HLA-peptide tetram

134 kappa GFR values obtained in potential renal transplant donors versus frequencies indicates a mean va

135 The transplant donor was an HLA-identical sibling (n = 35) o

136 on, the renal function of 80 potential renal transplant donors was measured using only external radia

137 Homozygous CCR5-Delta32/Delta32 stem cell transplant donors were used to produce HIV-cleared AIDS

138 All deceased solid organ transplant donors with COVID-19 testing results from Mar

139 In murine models, treatment of transplant donors with human AAT resulted in an increase

140 we investigated the effect of pretreating BM transplant donors with IL-18 on the severity of acute GV

141 Pretreatment of allogeneic BM transplant donors with IL-18 significantly improved surv

142 sparing the GVL, based on oral treatment of transplant donors with recipient Ags, associated with th